Tarsus Pharmaceuticals (NASDAQ: TARS) announced the acquisition of Alkeus Pharmaceuticals, expanding its leadership in eye care and retinal disease treatments. The company also completed an oversubscribed $125 million private placement, providing additional capital to support the integration, pipeline development, and future growth initiatives. Sector: Biotechnology / Ophthalmology Key Highlights 🤝 Acquiring Alkeus Pharmaceuticals 👁️ Expands Tarsus' leadership in eye care and retinal diseases 💰 Completed an oversubscribed $125 million private placement 🧬 Financing supports pipeline development and strategic growth 🚀 Strengthens the company's long-term ophthalmology portfolio Why It Matters The acquisition broadens Tarsus' ophthalmology pipeline, while the successful financing enhances its financial flexibility to accelerate product development and expand its leadership in eye care. Read More: https://www.thinksabio.com/reports/isr/TARS